comparemela.com

Latest Breaking News On - Will sevush - Page 1 : comparemela.com

Trump and Biden Both Hate Pharma—Investors Shouldn t

The drug sector just had one of its worst years ever relative to the S&P 500 and now faces political attacks, but investors should focus on the value.

Barack obamaBill clintonEli lillyAsad haiderGoldman sachsFederal reservePharmaceutical indexPharma indexWill sevushHate pharma

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.

United statesBristol myersJared holzEli lillyLilly mounjaroBristol myers squibbNovo ozempicNovo nordiskDrug administrationPharmaceutical indexWill sevush

Never Mind Covid, Investors Want a Pfizer Obesity Pill

The pharmaceutical company’s silence on oral obesity drug worries investors

Eli lillyDavid risingerAlbert bourlaSteva scalaGabby jonesNovo nordiskWall streetWill sevushLeerink partnersChief executive officer albert bourlaWsjfinance marketsFinancial investment servicesHealthcare life sciencesBanking creditFinancial servicesInvesting securities

Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills What to Know

Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills easier to take, cheaper to make might have the biggest long-term impact.

Chris shibutaniGoldman shibutaniDaniel baumEli lillyMichael nedelcovychJosh nathan kazisGraig suvannavejhLilly orforglipronDrug administrationCiti researchGoldman sachsTerns pharmaceuticalsNovo nordiskStructure therapeuticsWill sevushArticle normal

Lilly, Pfizer and Others Are Working on Obesity Pills What to Know

Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills easier to take, cheaper to make might have the biggest long-term impact.

Chris shibutaniMichael nedelcovychEli lillyJosh nathan kazisGoldman shibutaniDaniel baumLilly orforglipronGraig suvannavejhGoldman sachsDrug administrationCiti researchTerns pharmaceuticalsNovo nordiskStructure therapeuticsWill sevushArticle normal

vimarsana © 2020. All Rights Reserved.